End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.58 CNY | +0.67% | +1.40% | -15.13% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.13% | 4.51B | C+ | ||
+35.04% | 5.92B | B- | ||
-9.75% | 3.15B | B- | ||
+2.14% | 3.1B | C | ||
-6.82% | 2.42B | - | D+ | |
+47.87% | 1.97B | - | ||
-7.89% | 1.68B | - | - | |
+0.09% | 1.65B | - | - | |
-12.97% | 1.53B | C- | ||
+33.40% | 1.38B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002603 Stock
- Ratings Shijiazhuang Yiling Pharmaceutical Co., Ltd.